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AchR antibodies show a complex 
interaction with human skeletal 
muscle cells in a transcriptomic 
study
Yu Hong1*, Xiao Liang2 & nils erik Gilhus1,2
Acetylcholine receptor (AchR) antibodies are the most important pathogenic marker in patients with 
myasthenia gravis (MG). the antibodies bind to AchRs on the postsynaptic membrane, and this leads 
to receptor degradation, destruction, or functional blocking with impaired signal at the neuromuscular 
junction. In this study, we have explored the effects of AChR antibodies binding to mature human 
myotubes with agrin-induced AchR clusters and pathways relevant for AchR degradation using bulk 
RnA sequencing. protein-coding RnAs and lncRnAs were examined by RnA sequencing analysis. 
AChR antibodies induced marked changes of the transcriptomic profiles, with over 400 genes 
differentially expressed. Cholesterol metabolic processes and extracellular matrix organization gene 
sets were influenced and represent AChR-trafficking related pathways. Muscle contraction and cellular 
homeostasis gene sets were also affected, and independently of AChR trafficking. Furthermore, we 
found changes in a protein-coding RNA and lncRNA network, where expression of lncRNA MEG3 
correlated closely with protein-coding genes for cellular homeostasis. We conclude that AchR 
antibodies induce an active response in human skeletal muscle cells which affects key intra- and 
extracellular pathways.
AChR antibodies represent the main pathogenic marker of the autoimmune disease myasthenia  gravis1. At the 
neuromuscular junction (NMJ), AChR antibodies exert their effect by cross-linking AChR receptors in the 
muscle cell membrane, and this leads to degradation through antigenic  modulation2. The antibodies also bind 
complement and induce complement-mediated destruction of the AChR receptors and the membrane structure. 
AChR can in addition be blocked by direct antibody-receptor  binding1. The main immune region (MIR) for 
AChR antibody binding locates at the α subunit of both adult type and fetal type  AChR3–5.
The maintenance and stability of AChRs at the NMJs is a balanced, dynamic  process6. Agrin released from 
the presynaptic membrane aggregates AChRs through agrin-LRP4-MuSK  pathways7. Cholesterol and extra-
cellular matrix also play roles in stabilizing AChR  clusters8,9. The AChR antibodies from MG patients bind to 
AChRs and break this balance. It has been reported that AChR internalization can be triggered by both AChR 
antibodies and α-bungarotoxin binding with quantum  dots10,11. One study found that clathrin and caveolin were 
both required for endocytosis of AChRs in Xenopus primary muscle  cells10. Another study found that AChRs 
were internalized via an endocytic pathway in C2C12 and Chinese hamster ovary cell lines, distinct from the 
clathrin-mediated caveolar  pathway11. Cytoskeleton structures are required for AChR internalization after the 
binding of AChR  antibodies10,11.
Current knowledge regarding AChR internalization is largely based on animal cell lines expressing AChRs 
and focused on a few AChR relevant pathways. The mechanisms of antibody-induced AChR internalization in 
human skeletal muscle cells have not been studied in detail. It is unclear whether the AChR antibodies influence 
additional skeletal muscle physiological functions after disrupting AChRs.
Elucidating the effect of AChR antibodies on human skeletal muscle cells using transcriptomic methods 
should help to reveal myasthenia gravis pathogenesis and to identify potential treatment targets. We have used 
human myotubes with mature sarcomere structures that express AChR clusters to explore their transcriptomic 
status after incubation with AChR antibodies by using RNA sequencing. The antibodies induced changes in the 
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transcriptome expression, involving both AChR trafficking and muscle physiology pathways. We identified a 
co-expression network including lncRNA MEG3, playing a role in cellular homeostasis maintenance, that was 
selectively deregulated by the AChR antibodies.
Results
AchR antibodies bind to AchRs on human myotubes. To establish a cell model that expressed 
AChRs (Fig. 1A,B), human primary myoblast cells were differentiated into myotubes (Fig. 1C). Mature myo-
tubes were observed from day 4–5 after initiating the differentiation (Fig. 1C). The differentiation efficiency of 
myotubes reached 70% at differentiation day 5 (Fig. S1). Spontaneous, unclustered AChRs were formed on the 
myotubes (Fig. 1D-i). Mature myotubes had sarcomere structure and expressed myosin filament (Fig. 1E).
AChRs on the postsynaptic membrane are clustered and stabilized by agrin released from the axon terminal 
at the NMJ in vivo7. In our study, to induce AChR clusters, recombinant mice agrin (300 ng/ml) was added 
to skeletal muscle cells from differentiation day 1–2, and typical AChR clusters were visualized after 1–2 days 
(Fig. 1D-ii). To explore the effect of AChR antibodies on myotubes with AChR clusters, the recombinant mono-
clonal AChR antibody mAb198, that targets the main immune region of AChR, was added overnight (16 h) 
to agrin-treated myotubes at day 4–6. Previous studies have shown that mAb198 is able to crosslink adjacent 
AChRs and induce AChR  internalization2. In our system, mAb198 bound to both unclustered and clustered 
AChRs (Fig. 1D).
AChR antibodies induced marked changes in transcriptomic profiles. To explore the effect of the 
AChR antibody on mature human myotubes, bulk RNA sequencing was conducted on three groups of skeletal 
muscle cells; Agrin−/Ab−, Agrin+/Ab−, and Agrin+/Ab+ (Fig. 1A). Four biological replicates were included for 
each group. The polyA enrichment method was applied when building RNA libraries. In average, 40 million 
paired-end reads were generated from each sample. A standard RNA sequencing data analysis workflow was 
applied (Fig. S2). The adapters were trimmed. Raw sequencing data was quality checked, and the reads with low 
quality were removed. Clean reads were then aligned to the reference genome (GRCh38), which has included 
more than 60,000 protein-coding, pseudo, and non-coding genes. Reads that were mapped to specific genes were 
counted.
To observe the AChR antibody-induced effect on transcriptomic profiles of skeletal muscle cells at a wide-
spread level, we first constructed a multidimensional scaling plot based on principle component analysis 
(Fig. 2A). This plot showed both a batch effect (Fig. 2A-i) and an AChR antibody treatment effect (Fig. 2A-ii). 
Then we measured the sample and group similarities by calculating the Pearson correlation coefficients between 
all samples and between all groups for the whole RNA expression dataset (Fig. 2B). The AChR antibodies induced 
marked changes in the transcriptomic profile of the skeletal muscle cells at both sample (Fig. 2B-i) and group 
level (Fig. 2B-ii).
To determine the genes that were differentially expressed (DE) by the AChR antibody, we conducted dif-
ferential expression analysis. A generalized linear model considering the batch effect was used. After adjusting 
for batch effects, we found that 410 protein-coding RNAs, 20 pseudogene RNAs, 3 antisense RNAs, and 9 lncR-
NAs were expressed differently in the Agrin+/Ab+ group compared with the Agrin+/Ab− group (Padj < 0.05) 
(Fig. 2C). Table S1 lists the 30 protein-coding RNAs that showed the biggest difference in expression with and 
without AChR antibodies. Table S2 lists similar information for the 9 DE lncRNAs and the 3 antisense RNAs.
De protein-coding RnAs were enriched in distinct functional gene sets. To explore if the DE 
protein-coding RNAs were enriched in functional gene groups, we conducted gene ontology enrichment analy-
sis, which implemented a hypergeometric model to examine whether the number of DE genes belonging to one 
functional gene set was higher than expected. The gene ontology analysis showed that DE genes were enriched 
in pathways regulating the extracellular matrix, actin cytoskeleton, and myosin filament (Fig. 3A-i,ii), and also 
for genes regulating cholesterol metabolic processes and circadian rhythms (Fig. 3B-i,ii). Several genes encoding 
extracellular matrix proteoglycans, including collagen (COL12A1, COL4A2), aggrecan (ACAN) and versican 
(VCAN), showed an increased expression after AChR antibody incubation (Fig.  3C-i). The DE actin family 
genes included ACTB, ACTA2, ACTC1, and ACTG1, and the myosin family genes included MYH1, MYH2, 
MYH3, MYH9, MYH15, MYL12A, MYLPF (Fig. 3C-ii). Regarding the cholesterol metabolic process, the gene 
VLDLR was down-regulated, whereas DHCR24, DHCR7 and LSS were up-regulated (Fig. 3C-iii). Also, a cho-
lesterol homeostasis-related protein, LRP1, was up-regulated after AChR antibody treatment (Table S1). Several 
key regulators of circadian rhythms including Per (PER1, PER3) and Rev-erba (NR1D1, NR1D2), together with 
MET and CXCL1 which regulate cell responses to external stimuli, were differentially expressed (Fig. 3C-iv).
time series analysis reveals expression patterns of protein-coding RnAs. Having identified the 
DE genes and functional gene clusters affected by the AChR antibody, we explored the genes being specifically 
involved in the AChR trafficking process. First, we examined the three biological consecutive groups: Agrin−/
Ab−, Agrin+/Ab−, and Agrin+/Ab+ (Fig. 1A), and conducted a short time series analysis for all the protein-
coding RNAs (Fig. 4)12. The K-means clustering algorithm was applied to cluster the genes with a similar expres-
sion pattern across the three groups into one  cluster12. In total ten clusters were characterized. The agrin at NMJ 
exerts its effect on the AChR synthesis pathway, while AChR antibodies act on the AChR degradation pathway 
(Fig. 1B). Clusters with opposite trends in the Agrin+/Ab− (versus Agrin−/Ab−) and the Agrin+/Ab+ (versus 
Agrin+/Ab−) groups were classified as AChR trafficking related (Cluster 1–4) (Fig. 4). Clusters with a deviating 
trend only in the Agrin−/Ab− group were classified as muscle physiology associated (Cluster 5–7) (Fig. 4).
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AChR antibodies induced changes in AChR trafficking and muscle physiology related path-
ways. We identified which genes from the AChR trafficking related gene clusters (Cluster 1–4) and from the 
unrelated clusters (Cluster 5–7) were affected by the AChR antibody. We performed intersections between the 
410 DE protein-coding genes and each of the two cluster groups (Fig. 5). We found 51 DE genes in the AChR 
trafficking related clusters (Fig. 5A). They were enriched in gene sets of cholesterol metabolic processes (ACTA2, 
LSS, DHCR7, MVK, PBX1), glycosaminoglycan binding (TNXB, ACAN, ADAMTS5, HBEGF) and transcrip-
tion factor activity (NFIL3, PLSCR1, KLF4.) (Fig. 5B). 94 DE genes were identified in muscle physiology path-
way associated clusters (Fig. 5C). Genes for cellular homeostasis related pathways were enriched (rhythmic pro-
cess, cellular response to wound and lipid.) (Fig. 5D-i), and also muscle contraction genes (muscle contraction, 
myosin filament, contractile fiber.) (Fig. 5D-i,ii).
Figure 1.  Skeletal muscle cell differentiation and AChR antibody binding to AChRs. (A) Three groups (Agrin−/
Ab−, Agrin+/Ab− and Agrin+/Ab+) of differentiated skeletal muscle cells were examined. (B) Agrin and AChR 
antibodies affects AChR dynamics. (C) Differentiated and undifferentiated skeletal muscle cells in culture. (D) 
AChR antibodies bound to both clustered (agrin-treated) and unclustered (no agrin) AChRs on myotubes. 
AChRs were stained with the AChR antibody (mAb198). (E) Mature myotubes expressed myosin proteins.
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LncRnA and protein-coding RnA co-expression networks showed an association between 
lncRNA MEG3 and cellular homeostasis. Long noncoding RNAs (lncRNAs) are extensively involved 
in biological  regulation13,14, and they are more species- and tissue-specific than protein-coding  RNAs15. 9 DE 
lncRNAs were identified in the Agrin+/Ab+ group compared with the Agrin+/Ab− group. In order to explore 
the roles of the DE lncRNAs and their regulatory targets in the presence of AChR antibodies, a lncRNA and 
protein-coding RNA co-expression network was constructed based on the Pearson correlation efficient. The 
410 DE mRNAs and 9 DE lncRNAs were included. mRNA-lncRNA pairs with coefficient > 0.9 (positive cor-
relation) or < − 0.9 (negative correlation) were defined as correlated pairs. We found that the lncRNAs MEG3, 
RP11-184M15.1, and SNHG3 were co-expressed with several protein-coding RNA groups (Fig. 6A). MEG3 in 
particular showed an association with intracellular homeostasis related pathways, affecting the protein-coding 
gene sets of circadian rhythms, multicellular homeostasis and response to external stimuli (Fig. 6B–D).
Validation of RnA sequencing using Real-time quantitative pcR (Rt-qpcR). Six genes (ACTA2, 
ACTC, ACTG1, ARNTL, PER3, NR1D2) from relevant pathways and one lncRNA (MEG3) were chosen for 
validation of the RNA sequencing results by using RT-qPCR. RT-qPCR was conducted using the same RNA 
samples as for the sequencing. RT-qPCR and RNA sequencing showed the same trend for all seven genes (Fig. 7, 
Fig. S4).
Discussion
We have found that treatment of well-developed human skeletal muscle cells in culture with AChR antibodies 
leads to extensive changes in the expression of both protein-coding RNAs and lncRNAs. More than 400 genes 
were differentially expressed after AChR antibody incubation. Those genes were enriched in distinct functional 
groups including formation and maintenance of both AChR-trafficking dependent and independent processes. 
Pathways relating to the extracellular matrix, regulation of cholesterol metabolism, actin and myosin gene family, 
and intracellular homeostasis related pathways were involved. Furthermore, lncRNAs that regulate intracellular 
homeostasis showed a change in expression.
Multiple genes involved in the cholesterol metabolic process were up- or down- regulated. Cholesterol is an 
important component of the lipid bilayer cell membrane structure. Cholesterol influences a variety of AChR-
related biological processes including AChR synthesis, endocytosis, recycling, and AChR cluster stability (Fig. 8)8. 
Cholesterol is an essential partner of AChR both on the cell membrane and for intracellular AChR  trafficking8,16. 
The AChR trafficking process needs cholesterol already in the endoplasmic reticulum and Golgi  apparatus8. A 
cholesterol recognition motif in the transmembrane domain of several AChR subunits has been  identified17,18. 
Depletion of cholesterol will promote AChR  degradation19. Our study illustrates and supports the importance of 
cholesterol for AChR and AChR function. Sphingolipids, another component of the lipid raft on the post-synaptic 
membrane, are also associated with AChR  trafficking20. One study showed that genes regulating biosynthesis of 
sphingolipids were dysregulated in cultured cells from patients with MG and AChR  antibodies21. Furthermore, we 
found a cholesterol metabolism related protein, LRP1, to be up-regulated after AChR antibody treatment. LRP1 
is involved in several biological processes that maintain cholesterol  homeostasis22,23. LRP1 is also a membrane 
vesicle-trafficking protein. LRP1 can bind more than 40 extracellular ligands and membrane receptors, and the 
molecule helps transporting its ligands into the  cytoplasm24. LRP1 could act as a cargo protein for AChR during 
AChR internalization, or alternatively regulate AChR by influencing cholesterol metabolism.
The changes in RNA expression induced by the AChR antibody influence extracellular matrix molecules. 
AChR autoantibodies bind to the extracellular part of the  receptor1. Extracellular matrix is important for tissue 
repair and  regeneration25,26, and its glycoproteins constitute important components of the  NMJ27. Specific col-
lagen and laminin protein isoforms play important roles in maintaining the topological structure of the NMJ 
and regulating AChR  maturation9. In our study, several extracellular matrix components including collagen IV, 
aggrecan, and versican were up-regulated by the AChR antibody. Further, our analysis showed that the glycosa-
minoglycan binding gene cluster was linked to AChR trafficking processes. Previous studies of both MG patients 
and animals have showed a dysregulation of extracellular matrix molecules in the skeletal muscle cells of patients 
with MG and in experimental autoimmune myasthenia gravis (EAMG)  models28,29. Interactions between extra-
cellular matrix organization, AChR trafficking, and AChR antibodies need further studies.
Multiple actin family genes were up- or down-regulated by the AChR antibody incubation. The internalization 
of AChR vesicles is in part controlled by the intracellular  cytoskeleton10,11. The dynamic process of actin polymer-
ization and turnover is actively involved in internalization of AChR and other membrane receptors (Fig. 8)11,16,30. 
Since the membrane receptor internalization requires actin-assembling dynamics, AChR internalization might 
inversely influence actin gene expression. One hypothesis is that AChR internalization and endocytosis needs 
a fast cycling of actin polymerization and turnover. This should lead to higher levels of non-polymerized actin, 
which should again inhibit cytoskeleton gene expression. Another possibility is that the intracellular endosome 
transport needs a less dense environment. A high cytoskeleton density should inhibit the endosome movement. 
Figure 2.  Transcriptome profiles of differentiated skeletal muscle cells and the effect of AChR antibodies at 
widespread level. (A) The principle component analysis showed both a batch effect (i) and an AChR antibody 
treatment effect (ii). Within each batch, the antibody treated samples shift to the left for the first component 
(x-axis) compared with non-antibody treated groups (ii). Contr: Agrin−/Ab−; Agrin: Agrin+/Ab−; Ab: Agrin+/
Ab+. (B) Transcriptome similarities between samples (i) and groups (ii) were calculated based on Pearson 
correlation coefficient. Incubation with AChR antibodies gave marked changes in the transcriptomic profiles. 
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Figure 3.  Gene set enrichment analysis of DE genes. (A) 29 significantly enriched gene sets for cellular 
components were identified. The top 15 sets are listed (i) and all 29 illustrated by a semantic similarity-based 
scatter plot (ii). Enriched gene sets included extracellular matrix, actin cytoskeleton and the myosin gene family. 
(B) 225 significantly enriched gene sets for biological processes were identified. The top 15 sets are listed (i) 
and the top 30 illustrated by a semantic similarity-based scatter plot (ii). Enriched gene sets included rhythmic 
processes, and cholesterol and lipid metabolic processes. (C) DE genes reflecting extracellular matrix (i), actin 
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A previous study found in fact significantly enriched gene sets of actin cytoskeleton and actin filament in EAMG 
rats compared with controls in an RNA microarray  study28.
Our study showed that an AChR antibody induced changes of muscle contraction related pathways, includ-
ing the muscle myosin complex and myosin filament gene sets. Myosin family genes are key components of the 
sarcomere (Fig. 8) and are expressed in mature myotubes (Fig. 1). Instead of being directly linked to the AChR 
trafficking process, our data indicated that such effects seemed to be mediated by alternative pathways or were 
indirect consequences of the AChR internalization process. As both muscle contraction and cellular homeo-
stasis related pathways had similar expression patterns in our model, we hypothesis that muscle contraction is 
influenced by the breakdown of cellular homeostasis pathways induced by AChR antibodies. Several studies 
have shown that myosin and muscle contraction related genes are influenced by AChR antibodies in muscle cell 
cultures or in  patients28,31,32. Maurer et al. showed that myofibril and sarcomere associated genes were dysregu-
lated in MG patient and EAMG rat  muscle28. Another study found that myosin II related genes were differentially 
expressed in cultured muscle cells from MG patients compared with healthy  controls31. The influence of AChR 
antibodies on muscle contraction related genes may have pathophysiological and clinical consequences.
Several lncRNAs were differentially expressed in the presence of AChR antibodies. We have built a protein-
coding RNA and lncRNA cooperation network. The lncRNA MEG3 correlated closely with intracellular homeo-
stasis gene groups including genes important for circadian rhythms, multicellular homeostasis and responses to 
external stimuli. MEG3 is best known as a tumor suppressor gene that activates  p5333,34. MEG3 seems to play a 
role in maintaining intracellular homeostasis in skeletal muscle cells, and its down-regulation in the presence 
of AChR antibodies may have functional consequences. Previous studies in EAMG rats have shown that gene 
groups controlling responses to stress and stimuli were dysregulated in their skeletal  muscles29,32.
AChR antibodies occur in vivo in myasthenia gravis patients where they induce muscle weakness. We have 
found that AChR antibodies induce an active response in cultured human skeletal muscle cells. An important 
limitation of our study is that it is an in vitro study of human cultured cells with a purified AChR antibody against 
the MIR of the AChR α subunit. Another limitation is that not all the cultured myoblasts differentiated into 
myotubes. We have optimized our differentiation conditions to reach a differentiation efficiency of around 70%. 
The expression of AChRs was most dense during the early stages of cell differentiation (during the first 7 days).
In summary, we have found that the well-known process of AChR internalization in the presence of an 
AChR antibody was accompanied by dysregulation of genes controlling cholesterol metabolism and extracellular 
Figure 4.  Short time series analysis in three consecutive groups of differentiated skeletal muscle cells. Contr: 
Agrin−/Ab−; Agrin: Agrin+/Ab−; Ab: Agrin+/Ab+. Ten clusters were generated using the K-means clustering 
algorithm based on the consecutive expression pattern of group Agrin−/Ab−, Agrin+/Ab−, and Agrin+/Ab+. 
Cluster 1–4 (in light blue) had opposite trends in group Agrin+/Ab− (versus Agrin−/Ab−) and group Agrin+/
Ab+ (versus Agrin+/Ab−), and were classified as AChR trafficking related clusters; Cluster 5–7 (in violet) had a 
deviated trend only in Agrin−/Ab− group when compared to the other two groups, and were classified as muscle 
physiology pathway associated clusters. Cluster 8–10 (in green) were the remaining clusters without a distinct 
relation to AChR antibodies.
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matrix. Muscle contraction and cellular homeostasis gene sets being independent of AChR trafficking were also 
dysregulated. The effects observed by us in vitro may contribute to the clinical picture of myasthenia gravis and 
point to potential treatment targets.
Materials and methods
cell culture. Human primary myoblast cells were purchased from a commercial source (Cook Myosite, US) 
and had been isolated from a female, healthy donor aged 32 years. The myoblasts were cultured with serum free 
growth medium (Cook Myosite) with 20% fetal bovine serum (Gibco, Thermo Fisher Scientific, US). When the 
cells had grown to 90–95% confluence, they were cultured with differentiation medium. Differentiation medium 
was composed of Myotonic serum free differentiation medium (Cook Myosite), 2% horse serum (Gibco) and 1% 
Insulin-Transferrin-Selenium (Thermo Fisher Scientific). 300 ng/ml agrin was added to the cultures 1–2 days 
after the switch to differentiation medium. 10 nM recombinant human AChR IgG antibodies (mAb198) (Abso-
Figure 5.  AChR antibodies induced changes of AChR trafficking and muscle physiology related pathways. 
(A, B) 51 genes were identified by intersecting between the AChR trafficking related gene clusters and the DE 
protein-coding genes (A). They were enriched for cholesterol metabolic processes, and glycosaminoglycan 
binding and transcription factor activity (B). (C,D) 94 genes were identified by intersecting between the muscle 
physiology associated clusters and DE protein-coding genes (C). They were enriched for cellular homeostasis 
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Figure 6.  LncRNA and protein-coding RNA co-expression network. (A) A co-expression network was built 
based on the correlation efficient between all DE protein-coding RNAs and lncRNAs. LncRNA MEG3, SNHG3, 
and RP11-184M15.1 were correlated with several protein-coding RNA groups. (B,C) Gene set enrichment 
analysis of lncRNA correlated with protein-coding RNAs. 29 enriched gene sets for MEG3 correlated protein-
coding RNAs, and one gene set (circadian rhythm) for SNHG3 correlated protein-coding RNAs were identified 
(B). The 29 enriched gene sets for MEG3 correlated protein-coding mRNAs were illustrated by a similarity-
based scatter plot (C). The enriched gene sets for lncRNA MEG3 included circadian rhythm, response to biotic 
stimuli, and positive response to external stimuli. (D) 19 out of 46 MEG3 correlated protein-coding RNAs 
belonged to cellular homeostasis-related gene sets.
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lute antibody, UK) were added to the culture medium at differentiation day 4–6, and incubated with the cell 
cultures for 16 h. Parallel control cultures without AChR antibodies were also examined. mAb198 is a highly 
purified IgG protein. All the antibodies have the same protein sequence, which includes an antigen binding 
site against MIR of the AChR α-subunit. Therefore, in order to avoid introducing additional batch effect when 
conducting high-throughput transcriptomic sequencing, control IgG was not included in the control groups 
without AChR antibodies.
Figure 7.  RT-qPCR validation for RNA sequencing results. Six genes (ACTA2, ACTC, ACTG1, ARNTL, 
PER3, NR1D2) from relevant pathways (actin cytoskeleton, circadian rhythm), and one lncRNA (MEG3) were 
validated.
Figure 8.  AChR antibody-induced effects on myotubes expressing AChR clusters. 1. Cholesterol is involved in 
AChR internalization, modulation and recycling. 2. The dynamic process of actin polymerization and turnover 
is involved in AChR internalization. 3. Multiple myosin family genes and muscle contraction pathway genes 
were differentially expressed. 4. AChR antibodies induced an active response of extracellular matrix molecules. 
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Immunofluorescence. For staining with mAb198, cells grown on coverslips were fixed with 4% paraform-
aldehyde diluted in phosphate-buffered saline (PBS) for 10 min. Cells were blocked using blocking buffer (PBS 
with 0.1% Tween, 1% BSA and 22.52 mg/ml Glycine) for 30 min at room temperature. mAb198 diluted 1:200 in 
blocking buffer were added to the cells and incubated overnight at 4 °C. After washing three times with PBS, the 
cells were incubated with Alexa fluor 488 goat anti-human IgG antibodies (Invitrogen, Thermo Fisher Scientific) 
diluted 1:400 for 50 min at room temperature. After three washings with PBS, cells were stained with ProLong 
Diamond Antifade Mountant with DAPI (Invitrogen). Coverslips with the cells were mounted to microslide, 
before observation under a Leica TCS SP5 Confocal microscope (Leica, Germany).
RnA sequence. Four replicates of AChR antibody-treated and untreated myotubes were included for RNA 
sequencing. Each pair of cell samples (AChR antibody-treated versus control) was seeded from the same passag-
ing cells. Cells were tested negative for mycoplasma contamination before RNA isolation. Total RNA was isolated 
from mature myotubes using RNeasy Mini Kit (QIAGEN). RNA quality and concentration were checked using 
Bioanalyzer and Qubit. RNA-seq libraries were established by the polyA enrichment  method35. The sequencing 
was conducted by StarSEQ (Mainz, Germany) using a Illumina Next Seq 500 platform. In average 40 million 
paired end reads (150 bp) were generated from each RNA sample. The workflow of the analysis process is shown 
in Fig. S2. Adapter was trimmed using Trimmomatic (version 0.38)36. Reads were aligned to human genome 
(GRCh38.84, Ensemble) using  HISAT237.
Differential expression analysis. Read counts were generated using HTSeq-count38. Differential expres-
sion analysis was conducted using the EdgeR (R package)39. A generalized linear model considering the batch 
effect was used for the analysis. A design matrix was applied considering both grouping (antibody versus no 
antibody) and batch effects (pairs of samples) to fit the model. The Cox-Reid profile-adjusted likelihood method 
was used to estimate  dispersion39. Quasi-likelihood F-tests were used to calculate which genes’ expression dif-
fered significantly. In EdgeR, counts per million reads (CPM) was used as measurement of RNA expression level, 
and fold change (FC) (log2 transformed) was used to determine the up- (> 0) or down-regulation (< 0) of RNA 
levels in the treatment group versus controls. We adjusted for multiple comparisons by using the false discovery 
rate method. Only genes with adjusted P value < 0.05 were considered as significantly differentially  expressed39. 
Since we had well-controlled baseline conditions and the same myotube differentiation stage in all groups, FCs 
were not filtered for DE genes.
principle component and gene ontology enrichment analysis. Principle component analysis was 
conducted using  EdgeR39. A multidimensional scaling plot was used to show inter-group differences and batch 
effects of samples. Gene ontology analysis was conducted using ClusterProfiler (R package) to cluster the sig-
nificantly differentially expressed genes based on biological processes and cellular components, using the over-
representation  test40. This statistic test implements a hypergeometric model to examine whether the number 
of selected genes under certain conditions is larger than  expected41. The P value was calculated based on the 
following formula:
where N refers to total number of background genes; M refers to the number of genes in one specific gene set 
within this background; n refers to the number of DE genes; k refers to the number of genes in this specific gene 
set that were DE genes. P value < 0.05 was considered statistically significance. Gene ontology lists were further 
visualized using semantic similarity-based scatter  plots42.
Short time series analysis. Short time series analysis was conducted using  STEM12. Protein-coding RNAs 
with reads per kilobase of exon per million reads mapped (RPKM) > 0.1 were included in the analysis. RPKM 
is a unit to measure RNA expression level of RNA sequencing results that has been normalized by both gene 
length and total reads. RPKM was log transformed and the baseline level (expression status of Agrin−/AChR 
Ab− group) was normalized to 0 during the data input. The K-means clustering algorithm was used to cluster 
genes with similar expression pattern. This algorithm calculates the minimum of the following formula:
where K refers to number of clusters; S1, S2,…, SK refer to each specific cluster; each cluster Si has a center ci which 
represents the mean of the genes x1, x2, …, xj assigned to this  clusteri; and T refer to Group number – 1 (here T 
is 2). Ten clusters by default was clustered, and the algorithm was performed for 20 series, each time with a dif-
ferent random start. The best performance was included for the final clustering.
Long non-coding RnA (lncRnA). The human genome (Ensemble, GRCh38.84) that we applied includes 
more than 7,000 identified lncRNAs. The HISAT2-HTseq-EdgeR work-flow was used to analyze differentially 
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co-expression network between mRnA and lncRnA. The DE mRNAs and lncRNAs were included 
to build a mRNA and lncRNA co-expression network. The Pearson correlation coefficient was calculated for 
all mRNA and lncRNA pairs. Only mRNA-lncRNA pairs with coefficient > 0.9 (positive correlation) or < − 0.9 
(negative correlation) was considered as correlated pairs. The mRNA-lncRNA correlated pairs were imported 
into Cytoscape to make a co-expression  network43.
Rt-qpcR. RNA sequencing results were confirmed using RT-qPCR and included 6 mRNAs and 1 lncRNA. 
cDNA was synthesised using SuperScript IV First-Strand Synthesis Kit (Invitrogen). Oligo(dT) primers were 
used during the cDNA synthesis process. The cDNA product was diluted 1:2 using diethylpyrocarbonate 
(DEPC)-treated water before introduced into the PCR system. The PCR amplification system (20 μl) included 
cDNA templates (2 μl), forward primer (1 μl), reverse primer (1 μl), PowerUp SYBR Green Master Mix (Applied 
Biosystems, Thermo Fisher Scientific, US) (10 μl) and DEPC-treated water (6 μl). The PCR amplification was 
conducted using Applied Biosystems 7500 Fast Real-Time PCR system Mix (Applied Biosystems). The PCR 
reaction was started at 50 °C 2 min (UDG activation), and 95 °C 2 min (Dual lock DNA polymerase enzyme), 
followed by 40 cycles of denature (95 °C °C for 15 s) and annealing/extend (60 °C for 1 min).
The relative standard curve method was used to calculate the expression level of target genes relative to 
internal reference genes. cDNA templates diluted 1:2, 1:20, 1:200, 1:2,000 and 1:20,000 were used to build the 
standard curve. For some target genes with low expression levels, dilutions of 1:2, 1:20, 1:200, 1:1,000 and 1:5,000 
were used. TUBB and PPIA were used as internal reference genes. Melting curve and agarose gel electrophoresis 
of PCR products were used to evaluate the specificity of PCR amplification. For PCR product electrophoresis, 
a mixture of the DNA products (5 μl) and 1 μl 6 × Blue/Orange Loading Dye (Promega, US) was run in 2.5% 
agarose gel containing 1 μg/ml ethidium bromide for 60 min at 80 V. A 50 bp DNA ladder (Fermentas, US) was 
used as a standard reference. Information of primers, PCR efficiency, PCR product electrophoresis and a typical 
standard curve are listed in Fig. S3.
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